On Tuesday, Alzamend Neuro, Inc. (NASDAQ:ALZN) announced its plans to initiate the first of five phase 2 clinical studies of AL001. The first study, in healthy human subjects, is expected to commence in the second quarter of 2025.

The study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.

The head coil will capture detailed images of lithium across the entire brain, making measuring its levels in different brain regions easier and helping determine the ideal dose of AL001 that offers better safety and effectiveness than lithium carbonate.

Also Read: EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential

The coil will also scan the whole brain to map key areas and track how lithium moves, improving our understanding of its effects.

In collaboration with Massachusetts General Hospital as its contract research organization, Alzamend aims to explore the unique properties of AL001 and its effects on lithium delivery in the brain compared to marketed lithium salts.

The study in healthy human subjects will serve as a baseline to evaluate AL001's targeted effectiveness and side effects in Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder patients.

Previous studies in mice have shown that AL001 ensures better brain absorption while maintaining lower levels of lithium in the blood, paving the way for safer and more efficient treatments.

Price Action: ALZN stock is up 0.87% at $0.89 during the premarket session at the last check on Tuesday.

Read Next:

• Asia Markets Dip While Europe Advance, Gold Retreats – Global Markets Today While US Slept

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article EXCLUSIVE: Alzamend Neuro To Start First Phase 2 Study For Lead Candidate In 2025 originally appeared on Benzinga.com

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.